CymaBay Therapeutics Inc. (NASDAQ:CBAY) shares, rose in value on Wednesday, 08/03/22, with the stock price up by 12.07% to the previous day’s close as strong demand from buyers drove the stock to $3.90.
Actively observing the price movement in the last trading, the stock closed the session at $3.48, falling within a range of $3.4994 and $4.0902. The value of beta (5-year monthly) was 0.69. Referring to stock’s 52-week performance, its high was $4.74, and the low was $1.67. On the whole, CBAY has fluctuated by 29.57% over the past month.
With the market capitalization of CymaBay Therapeutics Inc. currently standing at about $338.68 million, investors are eagerly awaiting this quarter’s results, scheduled for Mar 23, 2022 – Mar 28, 2022. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.3, which is expected to increase to -$0.25 for fiscal year -$1.23 and then to about -$1.29 by fiscal year 2023. Data indicates that the EPS growth is expected to be 3.10% in 2023, while the next year’s EPS growth is forecast to be -4.90%.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that CBAY’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium term indicators have put the stock in the category of 25% Sell while long term indicators on average have been pointing out that it is a 50% Buy.
8 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. The stock is rated as a Hold by 0 analyst(s), 8 recommend it as a Buy and 0 called the CBAY stock Overweight. In the meantime, 0 analyst(s) believe the stock as Underweight and 0 think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is Buy.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of CBAY currently trading nearly 19.60% and 46.14% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 71.90, while the 7-day volatility ratio is showing 8.68% which for the 30-day chart, stands at 8.18%. Furthermore, CymaBay Therapeutics Inc. (CBAY)’s beta value is 0.69, and its average true range (ATR) is 0.28. The company’s stock has been forecasted to trade at an average price of $10.25 over the course of the next 52 weeks, with a low of $7.00 and a high of $14.00. Based on these price targets, the low is -79.49% off current price, whereas the price has to move -258.97% to reach the yearly target high. Additionally, analysts’ median price of $10.00 is likely to be welcomed by investors because it represents a decrease of -156.41% from the current levels.
A comparison of CymaBay Therapeutics Inc. (CBAY) with its peers suggests the former has fared considerably weaker in the market. CBAY showed an intraday change of 12.07% in last session, and over the past year, it shrunk by 0.00%%. In comparison, Bristol-Myers Squibb Company (BMY) has moved lower at -0.40% on the day and was up 5.31% over the past 12 months. On the other hand, the price of Pfizer Inc. (PFE) has risen 0.34% on the day. The stock, however, is off 9.15% from where it was a year ago. Additionally, there is a gain of 1.93% for Xencor Inc. (XNCR) in last trading while the stock has seen an overall depriciation of -5.71%% over the past year. Other than that, the overall performance of the S&P 500 during the last trading session shows that it gained 1.56%. Meanwhile, the Dow Jones Industrial Improved by 1.29%.
Data on historical trading for CymaBay Therapeutics Inc. (NASDAQ:CBAY) indicates that the trading volumes over the past 10 days have averaged 0.52 million and over the past 3 months, they’ve averaged 811.13K. According to company’s latest data on outstanding shares, there are 87.80 million shares outstanding.
Nearly 0.20% of CymaBay Therapeutics Inc.’s shares belong to company insiders and institutional investors own 79.30% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 3.5 million shares as on Jul 14, 2022, resulting in a short ratio of 3.01. According to the data, the short interest in CymaBay Therapeutics Inc. (CBAY) stood at 4.14% of shares outstanding as of Jul 14, 2022; the number of short shares registered in Jun 14, 2022 reached 3.35 million. The stock has risen by 15.38% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CBAY stock heading into the next quarter.